Literature DB >> 23275613

Animal models of chronic liver diseases.

Yan Liu1, Christoph Meyer, Chengfu Xu, Honglei Weng, Claus Hellerbrand, Peter ten Dijke, Steven Dooley.   

Abstract

Chronic liver diseases are frequent and potentially life threatening for humans. The underlying etiologies are diverse, ranging from viral infections, autoimmune disorders, and intoxications (including alcohol abuse) to imbalanced diets. Although at early stages of disease the liver regenerates in the absence of the insult, advanced stages cannot be healed and may require organ transplantation. A better understanding of underlying mechanisms is mandatory for the design of new drugs to be used in clinic. Therefore, rodent models are being developed to mimic human liver disease. However, no model to date can completely recapitulate the "corresponding" human disorder. Limiting factors are the time frame required in humans to establish a certain liver disease and the fact that rodents possess a distinct immune system compared with humans and have different metabolic rates affecting liver homeostasis. These features account for the difficulties in developing adequate rodent models for studying disease progression and for testing new pharmaceuticals to be translated into the clinic. Nevertheless, traditional and new promising animal models that mimic certain attributes of chronic liver diseases are established and being used to deepen our understanding in the underlying mechanisms of distinct liver diseases. This review aims at providing a comprehensive overview of recent advances in animal models recapitulating different features and etiologies of human liver diseases.

Entities:  

Mesh:

Year:  2012        PMID: 23275613     DOI: 10.1152/ajpgi.00199.2012

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  70 in total

1.  Mouse models of liver fibrosis mimic human liver fibrosis of different etiologies.

Authors:  Allyson K Martínez; Luca Maroni; Marco Marzioni; Syed T Ahmed; Mena Milad; Debolina Ray; Gianfranco Alpini; Shannon S Glaser
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

2.  New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases.

Authors:  Jennifer R Ferrer; Attasit Chokechanachaisakul; Jason A Wertheim
Journal:  Curr Transplant Rep       Date:  2015-06-01

Review 3.  Progress, obstacles, and limitations in the use of stem cells in organ-on-a-chip models.

Authors:  Alexa Wnorowski; Huaxiao Yang; Joseph C Wu
Journal:  Adv Drug Deliv Rev       Date:  2018-06-06       Impact factor: 15.470

4.  A Synthetic-Biology-Inspired Therapeutic Strategy for Targeting and Treating Hepatogenous Diabetes.

Authors:  Shuai Xue; Jianli Yin; Jiawei Shao; Yuanhuan Yu; Linfeng Yang; Yidan Wang; Mingqi Xie; Martin Fussenegger; Haifeng Ye
Journal:  Mol Ther       Date:  2017-02-01       Impact factor: 11.454

5.  Brain-Derived Neurotrophic Factor and Supraoptic Vasopressin Neurons in Hyponatremia.

Authors:  Kirthikaa Balapattabi; Joel T Little; Martha Bachelor; J Thomas Cunningham
Journal:  Neuroendocrinology       Date:  2019-09-27       Impact factor: 4.914

6.  Research Resource: A Reference Transcriptome for Constitutive Androstane Receptor and Pregnane X Receptor Xenobiotic Signaling.

Authors:  Scott A Ochsner; Anna Tsimelzon; Jianrong Dong; Cristian Coarfa; Neil J McKenna
Journal:  Mol Endocrinol       Date:  2016-07-13

7.  Glibenclamide protects against thioacetamide-induced hepatic damage in Wistar rat: investigation on NLRP3, MMP-2, and stellate cell activation.

Authors:  Durgesh Kumar Dwivedi; G B Jena
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-31       Impact factor: 3.000

8.  Phylogenetic analyses of the hepatic architecture in vertebrates.

Authors:  Nobuyoshi Shiojiri; Harunobu Kametani; Noriaki Ota; Yusuke Akai; Tomokazu Fukuchi; Tomoka Abo; Sho Tanaka; Junri Sekiguchi; Sachie Matsubara; Hayato Kawakami
Journal:  J Anat       Date:  2017-12-04       Impact factor: 2.610

9.  Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues.

Authors:  Leah M Norona; Deborah G Nguyen; David A Gerber; Sharon C Presnell; Edward L LeCluyse
Journal:  Toxicol Sci       Date:  2016-09-07       Impact factor: 4.849

10.  Establishment of a hepatic cirrhosis and portal hypertension model by hepatic arterial perfusion with 80% alcohol.

Authors:  Lei Wang; Fu-Liang He; Fu-Quan Liu; Zhen-Dong Yue; Hong-Wei Zhao
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.